Tag: Nevro
Nevro announces launch of “only AI-driven technology in spinal cord stimulation”
Nevro Corporation has announced the US Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI—a responsive, personalised...
Nevro to highlight 25 scientific abstracts on spinal cord stimulation at...
Nevro Corporation has announced a series of data presentations supporting the use of the company's high-frequency (HFX) 10kHz spinal cord stimulation (SCS) therapy for...
Nevro announces acquisition of Vyrsa Technologies
Nevro Corporation has announced that it has acquired Vyrsa Technologies—a privately held medical technology company focused on a minimally invasive treatment option for patients...
Nevro announces “profound improvements” in non-surgical refractory back pain patients treated...
Nevro Corporation has announced the publication of new 24-month data from the SENZA-NSRBP multicentre randomised controlled trial (RCT) in the Journal of Neurosurgery: Spine. The...
Nevro announces new data demonstrating health economic benefits of 10kHz SCS...
Nevro Corporation has announced the publication of new data validating the health economic benefits of 10kHz therapy, the company’s proprietary, high-frequency spinal cord stimulation...
Two-year data indicate long-term effectiveness of Nevro’s SCS therapy in painful...
Nevro Corporation recently announced the publication of 24-month data from the SENZA painful diabetic neuropathy (PDN) randomised controlled trial (RCT)—the largest RCT to evaluate...
Nevro announces full US market launch of HFX iQ spinal cord...
Nevro Corporation announced today that it has now initiated the full US market launch of its HFX iQ spinal cord stimulation (SCS) system, following...
Nevro announces two late-breaking data presentations set for NANS 2023
Nevro Corporation has announced that two abstracts for clinical trials relating to painful diabetic neuropathy (PDN) and non-surgical back pain (NSBP) treatments have been...
Nevro announces US FDA approval of HFX iQ system to personalise...
Nevro Corporation has announced that it has received approval from the US Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS)...
Nevro announces first global manufacturing operation with Costa Rica expansion
Nevro Corporation announced recently that the US Food and Drug Administration (FDA) has approved its manufacturing operations in Costa Rica for the production of its proprietary...
Nevro announces positive coverage updates for treatment of painful diabetic neuropathy...
Nevro Corporation has announced that US health plan Aetna has updated its spinal cord stimulation (SCS) coverage policy to explicitly cover painful diabetic neuropathy...
High-frequency SCS demonstrates “substantial improvement” in health-related quality of life outcomes
Nevro Corporation has announced that the complete 12-month results from the SENZA-PDN randomised controlled trial (RCT), including health-related quality of life outcomes in patients with...
High responder rates, substantial pain relief and no explants among key...
Nevro Corporation has announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022, New Orleans, USA) supporting the use of...
Nevro announces upcoming presentation of new SENZA-PDN clinical data
Nevro Corporation has announced that data from the SENZA painful diabetic neuropathy (PDN) randomised controlled trial (RCT)—which the company says is the largest RCT to...
High-frequency SCS drives impactful outcomes for non-surgical refractory back pain patients
Following the recent introduction of key data supporting the use of high-frequency spinal cord stimulation (SCS) in the treatment of non-surgical refractory back pain...
Nevro announces publication of 12-month data on high-frequency SCS for non-surgical...
Nevro Corporation has announced online publication of 12-month data from the SENZA-NSRBP randomised controlled trial (RCT) in Journal of Neurosurgery: Spine. These data show that...
NANS 2022: New 18-month data show durability of high-frequency SCS for...
This year’s North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) saw 18-month data from SENZA-PDN—a randomised controlled trial (RCT) evaluating the...
Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...
Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
Nevro announces three key data publications on novel painful diabetic neuropathy...
Nevro has announced three clinical data publications on treating painful diabetic neuropathy (PDN) with 10kHz spinal cord stimulation (SCS) therapy—including 12-month data from the...
Nevro announces plans to appeal jury decision in spinal cord stimulation...
Nevro Corporation has provided an update on its position following a Delaware jury’s decision to award Boston Scientific US$20 million over patent infringements. The...
High-frequency SCS takes the stage to relieve chronic pain from diabetic...
Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...
Nevro announces FDA approval of 10kHz high-frequency SCS therapy for painful...
Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system for the treatment of chronic pain associated with...
News from NANS: 10kHz safe and effective for treating painful diabetic...
A multicentre study across 18 centres finds 10kHz safe and effective for the treatment of painful diabetic neuropathy. Sensory improvements were observed in many...
Nevro announce launch of a new medical device for the treatment...
Nevro today announced it has received approval from the US Food and Drug Administration (FDA) for the Senza Omnia spinal cord stimulation (SCS) system....
Nevro announces completion of patient enrolment in multicentre RCT of high...
Nevro has announced that it has completed patient enrolment in its prospective, multicentre randomised controlled trial (RCT) for the treatment of chronic pain for...
Stimwave address patent infringement lawsuit brought by Nevro
Stimwave issued a statement today in response to a complaint made by Nevro in Federal Court Delaware District last week alleging Stimwave is infringing...
Nevro files lawsuit for patent infringement against Stimwave
Nevro has announced that it has filed a lawsuit for patent infringement against Stimwave Technologies. The lawsuit, filed in the United States District Court...
Patent litigation update for Nevro–Boston Scientific case
In a press release, Nevro Corp has announced that it has filed with Boston Scientific a joint statement proposing dismissal of the declaratory judgement claims...
FDA approves Senza II Spinal Cord Stimulation System
The US Food and Drug Administration has approved the next-generation Senza II Spinal Cord Stimulation (SCS) System (Nevro) delivering HF10 therapy.
According to the company,...
Nevro receives CE mark for full-body MRI conditional labelling with the...
Nevro has received the CE mark for full-body magnetic resonance imaging (MRI) conditional labelling on the Senza Spinal Cord Stimulation (SCS) System delivering HF10...
Nevro files lawsuit for patent infringement against Boston Scientific in the...
Nevro Corp has announced that it has filed a lawsuit for patent infringement against units of Boston Scientific. The lawsuit, filed in the United States...
Blue Cross Blue Shield denies coverage for high-frequency spinal cord stimulation...
Blue Cross Blue Shield has denied coverage for high frequency spinal cord stimulation in at least two states. Outposts of the federation of...
